Pacific Biosciences of California, Inc. (PACB)
- Sector
- Life Sciences Tools & Services
- Last price
- $1.96
- As of
Kresmion compiles this page from PACB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full PACB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PACB on one page. Preview it with sample data, then open it live with a free account.
Preview the PACB dossierActive signals for PACB
- highCONSENSUS_BUY
3 tracked funds increased PACB this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 7.9%, EPS $-0.14 vs $-0.1297 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of PACB (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1807% to PACB (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1576% to PACB (2026Q2)
FREE, NO ACCOUNT
Every signal on PACB, as it fires
You are seeing 5 of 12 signals recorded on PACB since 2026-05-17.
The five above landed across 3 days. The other 7 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PACB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 69404D108 · 2026Q2 | $8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 69404D108 · 2026Q2 | $7.1M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 69404D108 · 2026Q2 | $7.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 69404D108 · 2026Q2 | $6.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 69404D108 · 2026Q2 | $4.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 69404D108 · 2026Q2 | $1.6M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 69404D108 · 2026Q2 | $173K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PACB
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PACB against its peers
PACB's operating margin of -346.2% ranks in the 10th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | PACB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 160M USD | 1.2B USD | 21 | 25 |
| Gross margin | 28.6% | 57.4% | 12 | 12 |
| Operating margin | -346.2% | -9.5% | 10 | 23 |
| Net margin | -341.5% | -6.8% | 10 | 25 |
| Return on equity | -10214.5% | -7.5% | 2 | 24 |
| P / E | n/a | 45.2x | n/a | 10 |
| 1 year | 12.6% | 33.3% | 25 | 25 |
Peers (25): OABI, CTKB, MLAB, DNA, MRVI, FTRE, CDXS, MXCT, SEER, ABCL, ADPT, SHC, BRKR, TXG, AVTR, RGEN, TECH, TEM, CRL, MEDP, MTD, ILMN, WAT, IQV, A. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PACB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PACB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PACB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.